Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Astellas Pharma Europe B.V.
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Diagnosis of asthma

• Patients treated with inhaled corticosteroid

• FEV1 (forced expiratory volume in 1 second)>60% to 80%

Exclusion Criteria:

• Respiratory infection within 2 weeks

• Asthma exacerbation within 90 days